01Inhibrx Biosciences missed Q3 earnings with an EPS of -$2.46 versus the -$2.38 consensus estimate, representing a 3.4% negative surprise.
02The company's stock trades at $77.66 with a $1.2B market capitalization following the November 13, 2026 earnings release.
03Recent earnings show deteriorating performance, with Q1 2026 posting a 50.3% negative surprise before improving in Q4, then worsening again in Q3.
04Revenue figures were not disclosed in the earnings report, limiting assessment of top-line performance and business momentum.
Earnings Results
Inhibrx Biosciences (NASDAQ:INBX) reported quarterly earnings results on November 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-2.46, missing the consensus estimate of $-2.38 by $0.08 per share. Revenue came in at , meeting the estimate of .
Company Overview
Inhibrx Biosciences's stock moved following the earnings release. The stock currently trades at $77.66 with a market capitalization of $1.2B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Inhibrx Biosciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.